Lowered liver enzymes and liver fat content in NAFLD. Modest improvements in insulin sensitivity and fasting glucose observed in T2D/MetS patients (via reduced systemic inflammation and enhanced GLP-1). Some studies reported reduced inflammatory cytokines, though effects on lipid profiles were minimal. This evidence concerns the gene GLP1R and metabolic syndrome.